14th– 20thSeptember 2013
281 7560000 10692000 259 261 257 276 262 279 1 0`````````````````````` 5 1 0 285 282 1 False 0 0 0 0 -1 304800 243 True 128 77 255 3175 3175 70 True True True True True 278 134217728 1 4 -9999996.000000 -9999996.000000 8 Empty 13260 39423 6750156 13421772 3368499 13395609 16777215 8 Citrus 22858575 22852950 (`@````````` 266 263 5 110183775 110178150
14th– 20thSeptember 2013
281 7560000 10692000 259 261 257 276 262 279 1 0`````````````````````` 5 1 0 285 282 1 False 0 0 0 0 -1 304800 243 True 128 77 255 3175 3175 70 True True True True True 278 134217728 1 4 -9999996.000000 -9999996.000000 8 Empty 13260 39423 6750156 13421772 3368499 13395609 16777215 8 Citrus 22858575 22852950 (`@````````` 266 263 5 110183775 110178150
14th– 20thSeptember 2013
281 7560000 10692000 259 261 257 276 262 279 1 0`````````````````````` 5 1 0 285 282 1 False 0 0 0 0 -1 304800 243 True 128 77 255 3175 3175 70 True True True True True 278 134217728 1 4 -9999996.000000 -9999996.000000 8 Empty 13260 39423 6750156 13421772 3368499 13395609 16777215 8 Citrus 22858575 22852950 (`@````````` 266 263 5 110183775 110178150
14th– 20thSeptember 2013
281 7560000 10692000 259 261 257 276 262 279 1 0`````````````````````` 5 1 0 285 282 1 False 0 0 0 0 -1 304800 243 True 128 77 255 3175 3175 70 True True True True True 278 134217728 1 4 -9999996.000000 -9999996.000000 8 Empty 13260 39423 6750156 13421772 3368499 13395609 16777215 8 Citrus 22858575 22852950 (`@````````` 266 263 5 110183775 110178150
14th– 20thSeptember 2013
281 7560000 10692000 259 261 257 276 262 279 1 0`````````````````````` 5 1 0 285 282 1 False 0 0 0 0 -1 304800 243 True 128 77 255 3175 3175 70 True True True True True 278 134217728 1 4 -9999996.000000 -9999996.000000 8 Empty 13260 39423 6750156 13421772 3368499 13395609 16777215 8 Citrus 22858575 22852950 (`@````````` 266 263 5 110183775 110178150Month | Week | Volume | No | Heading | Download | |
1 | Jan | 31 - 06 | 39 | 1 | Flashback 2011 | ![]() |
2 | Jan | 07 - 13 | 39 | 2 | Leishmaniasis |
![]() |
3 | Jan | 14 - 20 | 39 | 3 | Fogging in Dengue Control (Part I) |
![]() |
4 | Jan | 21 - 27 | 39 | 4 | Fogging in Dengue Control (Part II) |
![]() |
5 | Feb | 28 - 03 | 39 | 5 | Management of work - stress (part I) |
![]() |
6 | Feb | 04 - 10 |
39 | 6 | Management of work - stress (part II) | ![]() |
7 | Feb | 11 - 17 |
39 | 7 | Cancer - the Risk Factors |
![]() |
8 | Feb | 18 - 24 |
39 | 8 | Nipah Virus Infection |
![]() |
9 | Mar | 25 - 02 |
39 | 9 | Yellow Fever-Are we at risk? |
![]() |
10 | Mar |
03 - 09 |
39 | 10 | Attention Deficit Hyperactivity Disorder (ADHD)-(Part I) |
![]() |
11 | Mar | 10 - 16 |
39 | 11 | Attention Deficit Hyperactivity Disorder (ADHD)-(Part II) |
![]() |
12 | Mar |
17 - 23 |
39 | 12 | Crimean-Congo Haemorrhagic Fever |
![]() |
13 | Mar | 24 - 30 |
39 | 13 | The Immunization Programme- Financial Aspects (Part I) |
![]() |
14 | Apr |
31 - 06 |
39 | 14 | The Immunization Programme- Financial Aspects (Part II) |
![]() |
15 | Apr |
07 - 13 |
39 | 15 | Supportive Supervision (Part I) |
![]() |
16 | Apr | 14 - 20 |
39 | 16 | Supportive Supervision (Part II) |
![]() |
17 | Apr |
21 - 27 |
39 | 17 | Supportive Supervision (Part III) |
![]() |
18 | May |
28 - 04 |
39 | 18 | Effective Vaccine Management (Part I) |
![]() |
19 | May | 05 - 11 |
39 | 19 | Effective Vaccine Management (Part II) |
![]() |
20 | May | 12 - 18 |
39 | 20 | Effective Vaccine Management (Part III) |
![]() |
21 | May |
19 -25 |
39 | 21 | Effective Vaccine Management (Part IV) |
![]() |
22 | June | 26 - 01 |
39 | 22 | Health Related Quality of Life (HRQoL) |
![]() |
23 | June |
02 - 08 | 39 |
23 | Cost-Effectiveness (Part I) |
![]() |
24 | June | 09 - 15 |
39 | 24 | Cost-Effectiveness (Part II) |
![]() |
25 | June |
16 - 22 |
39 |
25 | Global Rotavirus Surveillance |
![]() |
26 | June | 23 - 29 |
39 | 26 | Investigating an Outbreak (Part I) |
![]() |
27 | July |
30 - 06 | 39 |
27 | Investigating an Outbreak (Part II) |
![]() |
28 | July | 07 - 13 |
39 | 28 | Diarrhoea Outbreak Report - Lindula |
![]() |
29 | July |
14 - 20 |
39 |
29 | Health Facility Micro-Planning (Part I) |
![]() |
30 | July | 21 - 27 |
39 | 30 | Health Facility Micro-Planning (Part II) |
![]() |
31 | Aug |
28 - 03 |
39 |
31 | Health Facility Micro-Planning (Part III) |
![]() |
32 | Aug | 04 - 10 |
39 | 32 | Ebola Haemorrhagic Fever-The Fact Sheet | ![]() |
33 | Aug | 11 - 17 |
39 |
33 | Pertussis Outbreak in the United States of America | ![]() |
34 | Aug | 18 - 24 |
39 | 34 | Vaccine Vial Monitor– Taking a Closer Look (Part I) | ![]() |
35 | Aug | 25 - 31 |
39 |
35 | Vaccine Vial Monitor– Taking a Closer Look (Part II) | ![]() |
36 | Sep | 01 - 07 |
39 | 36 | Evidence-Based Medicine (Part I) | ![]() |
37 | Sep | 08 -14 |
39 |
37 | Evidence-Based Medicine (Part II) | ![]() |
38 | Sep | 15 - 21 |
39 | 38 | Global Programme to Eliminate Lymphatic Filariasis | ![]() |
39 | Sep | 22 - 28 |
39 |
39 | Climate Change and Health (Part I) | ![]() |
40 | Oct | 29 - 05 |
39 | 40 | Climate Change and Health (Part II) | ![]() |
41 | Oct | 06 - 12 |
39 |
41 | Dengue-The Antibody Response (Part I) | ![]() |
42 | Oct | 13 - 19 |
39 | 42 | Dengue-The Antibody Response (Part II) | ![]() |
43 | Oct | 20 - 26 |
39 |
43 | Novel Corona Virus Infection | ![]() |
44 | Nov | 27 - 02 |
39 | 44 | Adverse Events Following Immunization (Part I) | ![]() |
45 | Nov | 03 -09 |
39 |
45 | Adverse Events Following Immunization (Part II) | ![]() |
46 | Nov | 10 - 16 |
39 | 46 | Critical Appraisal (Part I) | ![]() |
47 | Nov | 17 -23 |
39 |
47 | Critical Appraisal (Part II) | ![]() |
48 | Nov | 24 - 30 |
39 | 48 | Cellular Phones and Cancer Risk | ![]() |
49 | Dec | 01 -07 |
39 |
49 | Conducting an EPI Coverage Survey | ![]() |
50 | Dec | 08 - 14 |
39 | 50 |
EPI Coverage Survey 2012-Batticaloa District |
![]() |
51 | Dec | 15 -21 |
39 |
51 |
Global Routine Vaccination Coverage, 2011 |
![]() |
52 | Dec | 22 - 28 |
39 | 52 |
Behavioral Risk Factor Surveillance System (BRFSS) |
![]() |
COVID - 19 Daily Situation Report
|
COVID - 19 Situation Sri Lanka - Epidemiological Summary |
COVID - 19 Vaccination Summary
|
|
COVID-19 Death Analysis - (5-18) Age group |
Preparation Pfizer Vaccine |
Provisional Clinical Guidelines on COVID-19 |
COVID - 19 Hospital Preparedness Final |
To minimize COVID - 19 in the country |
SL - TL 2019 |
Timor Leste - Sri Lanka twining agreement thematic area 3 - 2019 |
CKDu Study 2017 |
Epid / WHO / NSF CKDu Study 2017 |
Health and Emergency Response - Flood and landslide 2018 |
Dengue
|
Advice's for patients with Dengue Fever who are on ambulatory care ( Sinhala / Tamil / English) |
Printable versions (Sinhala/Tamil/English) |
Triage of fever patients with suspected dengue and criteria for admission |
Timor Lestre - Sri Lanka twining agreement
Health and Emergency Response - Flood and landslide 2018 New
Introduction of Human Papillomavirus (HPV) Vaccine into the National Immunization Programme
-----------------------------------------
Advice's for patients with Dengue Fever who are on ambulatory care ( Sinhala / Tamil / English )
Printable versions ( Sinhala / Tamil / English )
Triage of fever patients with suspected dengue and criteria for admission
-----------------------------------------
Disease Surveillance in Flood Affected Areas
1. Public health measures to be adopted in the event of floods.
2. Health messages for public.
-----------------------------------------
Zika Leaflet ( Sinhala/English )
Immunization coverage assessment survey
Ebola Preparedness – Assessment in Sri Lanka
Polio Eradication Endgame Plan
Introduction of the Inactivated Polio Vaccine
Symposium on Challenges in Prevention and Control of Hepatitis C
Working guideline for the management of patients having Ebola Virus Disease (EVD)
Diagnosis of Ebola virus disease (EVD)
Haematological investigations of Ebola Virus disease (EVD) suspected patients
Before conducting any haematological investigations on suspected Ebola Virus disease (EVD) patients
Please contact,
Routine H399 (Weekly Return of Communicable Diseases) based disease surveillance system has been the driving hub for Sri Lankan...
A report has been received on 22nd March 2011 by the Epidemiology Unit of the Ministry of Health from the Regional Epidemiologist...
![]() |
|
Developed in Association with ![]() |